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Abstract. Several endocrine cell abnormalities have been 
reported in different segments of the gastrointestinal tract of 
patients with irritable bowel syndrome (IBS). These cells have 
specialized microvilli that project into the lumen; they func-
tion as sensors for the gut contents and respond to luminal 
stimuli (mostly ingested nutrients) by releasing hormones 
into the lamina propria, where they exert their effects via 
a paracrine/endocrine mode of action. Certain food items 
trigger the symptoms experienced by IBS patients, including 
those rich in fermentable oligo-, di- and monosaccharides, 
and polyols (FODMAPs). In this review, we present the argu-
ment that the effects of both FODMAPs and the proportional 
intake of proteins, fats and carbohydrates on IBS symptoms 
may be caused by an interaction with the gut endocrine cells. 
Since the gut hormones control and regulate gastrointestinal 
motility and sensation, this interaction may be responsible 
for abnormal gastrointestinal motility and the visceral hyper-
sensitivity observed in these patients. There is no consistent 
evidence that IBS patients suffer from food allergy. The role 
of gluten intolerance in the development of IBS symptoms in 
these patients remains a matter of controversy. Individual guid-
ance on food management, which includes restrictions in the 
intake of FODMAP-rich foods and testing diets with different 
proportions of proteins, fats and carbohydrates has been found 
to reduce the symptoms, improve the quality of life, and make 
the habitual diet of IBS patients more healthy.
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Introduction
Irritable bowel syndrome (IBS) is a chronic functional gastroin-
testinal disorder with a worldwide prevalence of 10-20% (1-15). 
The diagnosis of IBS is based mainly on the assessment of the 
symptoms, which are abdominal discomfort/pain, altered bowel 
habits and abdominal bloating/distension (1,4). Patients with IBS 
can be subdivided into four subtypes according to the Rome III 
criteria and based on the stool pattern: diarrhea-predominant 
(IBS-D), constipation-predominant (IBS-C), mixed diarrhea 
and constipation (IBS-M) and unclassified IBS (U-IBS) (16,17).
IBS is usually diagnosed in younger patients (i.e., <50 years 
of age) and is more common in women than in men (3-6,8,9,11, 
12,14,15,18,19). Although IBS is not known to be associated with 
the development of serious disease or with excess mortality, it 
considerably reduces the quality of life of patients (1,19-21). In 
addition to the increased morbidity caused by IBS, this condi-
tion represents an economic burden to society as a result of the 
overconsumption of healthcare resources by and low produc-
tivity of IBS patients (22).
IBS patients often associate their symptoms with specific 
food items, such as milk and milk products, wheat products, 
caffeine, certain meats, cabbage, onion, peas/beans, hot spices, 
fried foods and smoked foodstuffs (23-25). However, surveys 
of the diets of IBS patients have failed to detect any differences 
in diet composition between IBS patients and the community 
as regards the intake of energy, carbohydrates, proteins and 
fats (26-32). However, a study on food intolerance and IBS 
found that 62% of the subjects had either limited or excluded 
food items from their daily intake, and 12% of these subjects 
had made such drastic changes in their diet that nutritional 
deficiencies could be foreseen in the long term (33).
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Certain studies have found IBS patients to be intolerant to 
various alcoholic beverages and generally have a low alcohol 
consumption (23,29). However, other studies found that the 
alcohol intake in patients with IBS was the same as or higher 
than that in the background population (30,31). The common 
belief among IBS patients is that lactose is the main cause 
of their symptoms, and consequently, they often reduce their 
intake of milk and milk products (29,31,34,35). Milk and 
other dairy products are the most important dietary source 
of calcium, vitamin B2 (riboflavin) and phosphorus in the 
Western world (36). Thus, while IBS patients consume more 
products that are alternatives to milk, such as soy, rice and oat 
milk, they have a low daily intake of calcium, vitamin B2 and 
phosphorus (29).
IBS patients have a lower consumption of foods known to 
be rich in fermentable oligo-, di- and monosaccharides, and 
polyols (FODMAPs), such as spaghetti, pasta, rice, millet, 
couscous and buns than healthy controls (29). Moreover, IBS 
patients have lower consumptions of certain vegetables (raw 
vegetables, raw broccoli, paprika, onion, leeks, garlic, cabbage, 
tomatoes, mushrooms and green beans) (29). On the other hand, 
they consume more FODMAP-rich fruits and vegetables, such 
as grapes, pears, peaches, peas, mango, plums and melon (29).
The importance of dietary factors and the associations 
between diet and symptoms in IBS have been discussed in 
the literature (23,37-41). The aim of this review was to shed 
light on the possible interaction between dietary intake and gut 
hormones, and the importance of diet management in reducing 
the symptoms and improving the quality of life of IBS patients.
2. The role of diet in IBS
The effect of diet on IBS symptoms may be attributed to the 
interaction between poorly absorbed carbohydrates/fiber and 
the intestinal bacterial flora, or between ingested nutrients and 
the gut neuroendocrine system, and food allergy or intolerance.
Interaction between poorly absorbed carbohydrates/fiber 
and the intestinal bacterial flora. Certain short-chain carbo-
hydrates (FODMAPs) are poorly absorbed, resulting in a 
significant proportion of them reaching the distal small bowel 
and colon (42,43), where they provide a substrate for bacte-
rial fermentation. This results in the production of gas, with 
the consequent distension of the large intestine and increased 
intraluminal pressure. FODMAPs include fructose, lactose, 
sugar alcohols (sorbitol, maltitol, mannitol, xylitol and ismalt), 
fructans and galactans. Fructose and lactose are present in 
apples, pears, watermelon, honey, fruit juices, dried fruits, as 
well as milk and milk products. Polyols are used in low-calorie 
food products. Galactans and fructans are present in wheat, rye, 
garlic, onions, legumes, cabbage, artichokes, leeks, asparagus, 
lentils, inulin, soy, Brussels sprouts and broccoli (39,40,44). A 
low intake of FODMAPs has been found to reduce the gastroin-
testinal symptoms in patients with IBS (42,43,45,46).
Increasing the intake of dietary fiber is a standard recom-
mendation for patients with IBS (47). However, in clinical 
practice, increased fiber intake in these patients has been 
shown to increase the symptoms of abdominal pain, bloating 
and distension. The examination of the effects of fiber intake 
on IBS symptoms has revealed that increased fiber intake does 
not improve symptoms compared with a placebo or a low-fiber 
diet (47). However, it has been reported that the intake of 
soluble fiber is effective in improving overall IBS symptoms 
relative to consuming insoluble fiber (47-50).
The effects of FODMAPs and fiber on IBS symptoms 
are strongly associated with the intestinal flora. The domi-
nance of Clostridium spp. in the intestinal flora, which break 
down FODMAPs and fiber, results in gas production, with a 
consequent increase in the distension of the large intestine, 
causing abdominal discomfort or pain. Food supplements 
with beneficial bacteria, such as Lactobacillus spp. and 
Bifidobacterium spp. would result in a greater tolerance to 
both FODMAPs and fiber, since these bacteria do not produce 
gas on fermenting carbohydrates. It has been reported 
that the intestinal flora of IBS patients comprise fewer 
Lactobacillus spp. and Bifidobacterium spp. than the flora of 
healthy individuals (51,52).
Interaction between ingested nutrients and the gut neuroen-
docrine system. The gut endocrine cells are spread between 
the epithelial cells of the mucosa facing the gut lumen (1,53). 
They are present in all the segments of the gastrointestinal 
tract apart from the esophagus (1). There are several different 
populations of gut endocrine cells (22,32,53-55); the distribu-
tion, functions and modes of action of the most important types 
have been reported previously (22,32,53,56-68). Some of the 
different endocrine cell types are located only in specific areas 
of the gut, while others are found throughout the gut (53-55). 
Thus, serotonin- and somatostatin-secreting cells are found 
throughout the gastrointestinal tract, while those producing 
ghrelin and gastrin are found in the stomach; those producing 
secretin, cholecystokinin (CCK), gastric inhibitory peptide 
(GIP) and motilin are found in the upper small intestine, and 
those producing polypeptide YY (PYY), pancreatic polypep-
tide (PP) and enteroglucagon are located in the lower small 
intestine and large intestine (53-55). These cells have special-
ized microvilli that project into the lumen and function as 
sensors for the gut contents (mostly for nutrients), and respond 
to luminal stimuli by releasing their hormones into the lamina 
propria (Fig. 1) (69-81). The gut intraluminal contents of carbo-
hydrates, proteins and fats triggers the release of the different 
signaling substances (i.e., hormones) from the gut endocrine 
cells (1,53). These signaling substances may exert their actions 
locally on nearby structures (paracrine mode) or by entering 
the circulating blood and reaching distant targets (endocrine 
mode) (82). The gut endocrine cells interact and integrate with 
each other, and with the enteric nervous system (ENS) and the 
afferent and efferent nerve fibers of the autonomic nervous 
system and the central nervous system (CNS) (22,53,59,83). In 
doing so, they regulate several functions of the gastrointestinal 
tract, including visceral sensation, motility, secretion, absorp-
tion, local immune defense and food intake (22,53-55,83).
Several abnormalities in the gut endocrine cells have been 
described in IBS patients (84-100), as summarized in Table I 
and illustrated in Figs. 2 and 3. The etiology of these abnormal-
ities in sporadic (non-specific) IBS patients can be genetically 
inherited and/or caused by environmental factors. A genetic 
etiology is supported by the familial aggregation of IBS and 
the results of twin studies (101-111). Alternatively, endocrine 
cells have a rapid turnover, and it is possible that factors related 
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to luminal content, such as diet or bacterial flora can provoke an 
increase or decrease in the endocrine cell population (54,55). 
In post-infectious IBS (PI-IBS), the abnormalities in gut endo-
crine cells may be the result of endocrine/immune interactions 
(i.e., the endocrine/immune axis), which are in turn caused by 
low-grade inflammation following gastroenteritis in predis-
posed individuals (112,113).
As indicated in Table I, gastrointestinal hormone release 
is triggered by the intraluminal contents of nutrients; thus, the 
release of ghrelin, CCK and PYY is triggered by proteins and 
fat, and ghrelin release is suppressed by the presence of carbo-
hydrates. Consequently, while a diet that is poor in fat, proteins 
and carbohydrates would aggravate the symptoms in patients 
with IBS-D, a diet containing low levels of fat and proteins and 
high levels of carbohydrates would worsen the symptoms in 
patients with IBS-C. In patients with PI-IBS, the symptoms 
would be worsened by food rich in proteins and fat.
In IBS patients, the gut endocrine cells may be responsible 
for the abdominal pain/discomfort resulting from the aforemen-
tioned gas production and consequent increase in intraluminal 
pressure and large-intestinal distension following the break-
down of FODMAPs and fibers by the intestinal bacterial flora. 
An increase in the intraluminal pressure would possibly result 
in the release of serotonin and substance P into the interstitial 
fluid. Serotonin activates the submucosal sensory branch of 
the ENS, which conveys the sensation to the CNS, possibly 
causing the sensation of abdominal pain/discomfort (114,115). 
Furthermore, serotonin controls gastrointestinal motility and 
chloride secretion via interneurons and motor neurons, which 
may result in disturbances in both motility and gastrointestinal 
secretion (114,115).
Food allergy or intolerance. There is neither consistent evidence 
for an allergic response nor documented evidence for intolerance 
to a specific food in IBS (1,116-122). Although a food allergy 
mediated by mucosal mechanisms has been suggested for IBS 
(123,124), these mechanisms may play a role in only a subset 
of patients who may have atopy or PI-IBS (1,123,125). Different 
Figure 1. The gut hormones released into the interstitial fluid of the lamina 
propria in response to intraluminal nutrient content vary according to the 
proportions of (A) carbohydrates, (B) proteins and (C) fats. These hormones 
may act in an endocrine/paracrine manner or as neurotransmitters/neuro-
modulators of neurons in the ENS.
Figure 2. Ghrelin in the oxyntic mucosa of (A) a healthy subject, (B) a patient 
with diarrhea-predominant IBS (IBS-D), and (C) a patient with constipation-
predominant IBS (IBS-C).
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Table I. Summary of the abnormalities in the endocrine cell densities in different segments of the gastrointestinal tract of IBS 
patients, and the factors responsible for the release of gut hormones and the functions of these hormones.
  Endocrine
Gut segment cell type Released by Functions IBS-D IBS-C
Stomach Ghrelin Protein and fat ingestion. Increases gastric and intestinal High Low
   Suppressed by carbohydrate motility, and stimulates appetite
   ingestion. and food intake.
  Serotonin Adrenaline, acetylcholine, Activates the submucosal Normal High
   acidification, and increased sensory branch of the ENS,
   intraluminal pressure. inhibits gastric emptying,
    stimulates colonic motility,
    and accelerates small- and
    large-intestinal transit.
  Gastrin Intraluminal peptides, Stimulates gastric acid secretion High High
   amino acids, calcium, and histamine release, and
   amines, low pH, and stimulates contraction of
   prostaglandins. Release the LES and antrum.
   inhibited by somatostatin.
  Somatostatin Meal and acidification Inhibits gut exocrine and Low Low
   of the stomach. neuroendocrine secretion, and
    inhibits intestinal contraction.
Small intestine
  Duodenum CCK Intraluminal protein and fat. Stimulates pancreatic exocrine Low Normal
    secretion and growth, regulates
    food intake, inhibits gastric
    emptying, and stimulates
    gallbladder contraction and
    intestinal motility.
  Secretin Acidification of the intestinal Stimulates pancreatic bicarbonate Low Normal
   contents. and fluid secretion; inhibits
    gastric emptying; inhibits
    contractile activity of the small
    and large intestines.
  GIP Intraluminal glucose; Inhibits gastric acid secretion. Low Low
   amino acids and fat.
  Somatostatin Intraluminal glucose; Inhibits gastric acid secretion. Low Low
   amino acids and fat.
  Ileum Serotonin Intraluminal glucose; Inhibits gastric acid secretion. Low Low
   amino acids and fat.
  PYY Protein- and fat-rich meals. Delays gastric emptying, Normal High
    stimulates the absorption of
    water and electrolytes; major
    mediator of the ileal brake.
Large intestine
  Colon Serotonin Protein- and fat-rich meals. Delays gastric emptying, Low Low
    stimulates the absorption of
    water and electrolytes; major
    mediator of the ileal brake.
  PYY Protein- and fat-rich meals. Delays gastric emptying, Low Low
    stimulates the absorption of
    water and electrolytes; major
    mediator of the ileal brake.
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classes of antibodies (IgG) have been implicated in food-related 
allergies in IBS (126, 127). The results of studies on this subject 
are controversial, possibly sicne the tests used are not sufficiently 
sensitive or specific (31,116,117,123,124,128-133).
The association between IBS and celiac disease (CD) has 
drawn much attention of late. The breadth of the spectrum of 
symptoms in IBS means that there is the potential for overlap 
with CD symptomatologies. Thus, patients with CD presenting 
with relatively vague abdominal symptoms can be diagnosed 
as having IBS (39,40). Furthermore, the symptoms of both 
IBS and CD patients are triggered by the ingestion of wheat 
products. The reported prevalence of CD in IBS varies between 
0.04 and 4.7% (134-144). It has been suggested that IBS patients 
with wheat intolerance and who carry the genotype associated 
with CD (HLA DQ2 or DR3), but do not have typical sero-
logical markers or changes in small-intestine histology exhibit 
other immunological evidence of gluten reactivity and response 
to a gluten-free diet (145).
The augmentation of IBS symptoms by the ingestion of 
wheat products has been attributed to the content of the sugar 
polymers, fructans and galactans (38,146). In clinical practice, 
some IBS patients describe a reduction in symptoms upon eating 
a gluten-free diet. Although this has been dismissed by clini-
cians as a placebo effect, there is emerging new data regarding 
non-celiac gluten sensitivity (147). The existence of non-celiac 
gluten intolerance has been demonstrated by a double-blinded, 
randomized, placebo-controlled rechallenge trial (148). 
However, the diets of the subjects in that study excluded wheat 
products, which contain gluten, as well as fructans and galac-
tans. A recent placebo-controlled, cross-over study found no 
evidence of the specific effects of gluten in non-celiac gluten 
sensitivity (149). Thus, the role of gluten intolerance in IBS has 
yet to be clarified, and further studies are required.
3. Diet management in IBS
It is clear that IBS patients need guidance on diet management. 
Providing IBS patients with diet guidance has been found to 
reduce symptoms and to improve their quality of life (29,150). 
Furthermore, this guidance leads IBS patients to consume 
a more adequate diet in terms of the levels of vitamins and 
minerals, and makes them aware of all FODMAP-rich foods, 
the consumption of which they should either avoid or reduce. 
They also consume foods supplemented with Lactobacillus spp. 
Figure 3. Polypeptide YY (PYY)-immunoreactive cells in the colon of (A) a healthy subject and (B) a patient with irritable bowel syndrome (IBS).
Table I. Continued.
  Endocrine
Gut segment cell type Released by Functions IBS-D IBS-C
  Rectum PYY Protein- and fat-rich meals. Delays gastric emptying, Low Low
    stimulates the absorption of
    water and electrolytes; major
    mediator of the ileal brake.
  Enteroglucagon Intraluminal carbohydrates Inhibits gastric and pancreatic Low Low
   and fat. secretion, reduces gastric motility,
    and has also some incretin effect.
  Somatostatin Protein- and fat-rich meals. Delays gastric emptying, High High
    stimulates the absorption of
    water and electrolytes; major
    mediator of the ileal brake.
IBS, irritable bowel syndrom; IBS-D, diarrhea-predominant IBS; IBS-C, constipation-predominant IBS; LES, lower esophageal sphincter; 
GIP, gastric inhibitory peptide.
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and Bifidobacterium spp., which increase their tolerance to 
FOODMAPs (29).
Diet guidance should be individualized, since IBS patients 
have different tolerances to various FODMAP-rich foods, 
possibly due to differences in their intestinal flora. The aim 
of diet guidance should be to provide information about 
FODMAPs and their role in the symptoms of individual patients, 
and to instruct them to avoid such foods. Moreover, the effects 
of the proportional intakes of protein, fats and carbohydrates 
on their symptoms should be examined. In clinical practice, 
we have found that reducing the carbohydrate or fat intake and 
increasing the protein intake improves the symptoms in certain 
patients. In addition, IBS patients should be encouraged to 
consume foods that are supplemented with Lactobacillus spp. 
and Bifidobacterium spp. Other lifestyle factors, such as 
regular exercise and regular intake of probiotics, may augment 
the effect of diet management (151).
4. Conclusion
Diet triggers symptoms in IBS patients, possibly as a result of 
interactions with the gut endocrine cells, which are defective 
in IBS patients. The effects of the food content of FODMAPs 
and fiber on IBS symptoms are possibly mediated through gut 
endocrine cells. FODMAPs in the diet increase the osmotic 
pressure and provide a substrate for bacteria fermentation and 
gas production in the large intestine, resulting in abdominal 
distension. The increase in intestinal pressure may cause 
the release of serotonin and substance P, which in turn may 
result in the sensation of abdominal discomfort or pain. The 
protein, fat and carbohydrate content of ingested foods deter-
mine the amount and type of gut hormones released, which 
will in turn regulate and control gastrointestinal motility and 
sensation, that have been reported to be abnormal in IBS 
patients (152-179). Although it is possible that IBS patients 
suffer from gluten intolerance, further studies are required to 
confirm this before any definitive conclusions can be drawn. 
Guidance on diet management, including individually tailored 
restrictions of FODMAP-rich foods and the testing of protein-, 
fat- and carbohydrate-rich/poor diets reduce IBS symptoms 
and accordingly improve the overall management of the health 
of IBS patients.
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